BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.

about

BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.

Item

http://www.wikidata.org/entity/Q39620395

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

BMS-536924, an ATP-competitive ...... ppresses tumor growth in vivo.

@en

BMS-536924, an ATP-competitive ...... ppresses tumor growth in vivo.

@nl

type

Item

label

BMS-536924, an ATP-competitive ...... ppresses tumor growth in vivo.

@en

BMS-536924, an ATP-competitive ...... ppresses tumor growth in vivo.

@nl

prefLabel

BMS-536924, an ATP-competitive ...... ppresses tumor growth in vivo.

@en

BMS-536924, an ATP-competitive ...... ppresses tumor growth in vivo.

@nl

P1476

BMS-536924, an ATP-competitive ...... ppresses tumor growth in vivo.

@en

P2093

Qiao Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

Mechanisms of cancer drug resistance

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.

P304

689-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S80047

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275222174

http://www.w3.org/2001/XMLSchema#string

P698

25897243

http://www.w3.org/2001/XMLSchema#string

P932

4396459

http://www.w3.org/2001/XMLSchema#string